Up to today, acetylcholinesterase (AChE) is an attractive target for the treatment of Alzheimer’s disease, and acetylcholinesterase inhibitors represent the major approved drugs to treat this neurodegenerative disease (37). This evidence concerns the gene ACHE and Alzheimer disease.